

CORRECTION

Open Access



# Correction to: Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution

Vaia Florou<sup>1\*</sup>, Andrew E. Rosenberg<sup>1</sup>, Eric Wieder<sup>1</sup>, Krishna V. Komanduri<sup>1</sup>, Despina Kolonias<sup>1</sup>, Mohamed Uduman<sup>2</sup>, John C. Castle<sup>2</sup>, Jennifer S. Buell<sup>2</sup>, Jonathan C. Trent<sup>1</sup> and Breelyn A. Wilky<sup>1</sup>

## Correction to: *J ImmunoTher Cancer*

<https://doi.org/10.1186/s40425-019-0689-7>

Following publication of the original article [1], the authors have reported that the following sentence “While of the same IgG1 class as ipilimumab, preclinical data suggests this molecule may have enhanced activity against T regulatory cells.”

should be replaced with

“Ipilimumab and AGEN1884 are IgG1 class antibodies. AGEN1884 data show CTLA-4 inhibition and activity against T regulatory cells (reference 8).”

### Author details

<sup>1</sup>Department of Medicine, Division of Oncology, Sylvester Comprehensive Cancer Center at University of Miami Miller School of Medicine, 1475 NW 12th Avenue, Miami, FL 33136, USA. <sup>2</sup>Agenus Inc., 3 Forbes Road, Lexington, MA 02421, USA.

Published online: 06 November 2019

### Reference

1. Florou, et al. Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution. *J ImmunoTher Cancer*. 2019;7:213. <https://doi.org/10.1186/s40425-019-0689-7>.

The original article can be found online at <https://doi.org/10.1186/s40425-019-0689-7>

\* Correspondence: [vaia.florou@hsc.utah.edu](mailto:vaia.florou@hsc.utah.edu)

<sup>1</sup>Department of Medicine, Division of Oncology, Sylvester Comprehensive Cancer Center at University of Miami Miller School of Medicine, 1475 NW 12th Avenue, Miami, FL 33136, USA

Full list of author information is available at the end of the article



© The Author(s). 2019 **Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated.